Compositions and methods for diagnosis and therapy of disorders related to alterations of myh9
OwnerDaniel Schramek, Elaine Fuchsinventors
Life of this patent
Estimating the term…
Abstract
Provided are compositions and methods related to mutations in the Myh9 gene for aiding in diagnosing a subject as having an aggressive form of a cancer, for identifying an individual as a candidate for treatment with a nuclear export inhibitor, for determining whether tumor cells have defective p53 nuclear transportation, and for treating an individual diagnosed with an aggressive cancer.
Claims15
A method of aiding in diagnosing whether a subject has an aggressive form of a cancer, comprising:
- testing a sample of a tumor from the subject to determine a mutation in the Myh9 gene or low expression of the Myh9 gene relative to a control, wherein the presence of the mutation and/or the low expression aids in the diagnosis that the individual has an aggressive form of cancer.
A method for identifying an individual as a candidate for treatment with a nuclear export inhibitor comprising testing a sample of a tumor from the subject to determine a mutation in the Myh9 gene and/or low expression of the Myh9 gene relative to a control, wherein the presence of the mutation in the Myh9 and/or the low expression of the Myh9 gene relative to a control indicates that the individual is a candidate for therapy with a nuclear export inhibitor.
A method for determining whether tumor cells have defective p53 nuclear transportation comprising testing the tumor cells for a mutation in the Myh9 gene, wherein the presence of the mutation in the Myh9 gene determines that the cells have defective p53 nuclear transportation.
A method for treating an individual diagnosed with an aggressive cancer, wherein the aggressive cancer comprises cancer cells, which comprise a mutation in the Myh9 gene, comprising administering to the individual a composition comprising an effective amount of a nuclear export inhibitor.
Dependencies are inferred from the claim text.